A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Comparison of Graft Durability Among Lymphoma Patients Who Received Plerixafor in Combination with G-CSF for Primary Versus Failed Mobilization
2009
Biology of Blood and Marrow Transplantation
Preserved Fulltext
Projected 5-year OS P Cumulative 2-year NRM P Cumulative 5-year relapse mortality P HCT-CI low 43% (29-58) NS 25% (14-37) NS 29% (17-42) NS HCT-CI intermediate 38% (35-50) 18% (10-29) 37% (25-49) HCT-CI high 40% (21-59) 26% (12-43) 34% (16-53) PAM category 112 42% (27-59) NS 16% (7-28) NS 35% (20-50) NS PAM category 314 39% (29-49) 25% (17-33) 33% (24-42) ERS \ 3 59% (42-73) 0.0002 20% (10-33) NS 20% (10-33) 0.0172 ERS 5 3 43%(26-61) 22% (10-29) 34% (19-50) ERS . 3 20% (9-32) 33% (23-50) 44%
doi:10.1016/j.bbmt.2008.12.030
fatcat:qjr2pjdtrfggxblxtclerxzd5q